Maude Tessier - Jan 18, 2022 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role: Chief Business Officer
Signature: /s/ Douglas R. Carlson, as Attorney-in-Fact for Maude Tessier
Stock symbol: IKNA
Transactions as of: Jan 18, 2022
Transactions value $: $253,800
Form type: 4
Date filed: 1/20/2022, 03:30 PM
Next filing: Feb 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IKNA	Common Stock	Options Exercise	$114K	+38.9K	+135.16%	$2.94	67.7K	Jan 18, 2022	Direct
transaction	IKNA	Common Stock	Options Exercise	$102K	+24.6K	+36.34%	$4.15	92.3K	Jan 18, 2022	Direct
transaction	IKNA	Common Stock	Options Exercise	$37.3K	+8.27K	+8.95%	$4.51	101K	Jan 18, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKNA	Stock Option (Right to Buy)	Options Exercise	$0	-38.9K	-87.5%	$0.00	5.56K	Jan 18, 2022	Common Stock	38.9K	$2.94	Direct	F1
transaction	IKNA	Stock Option (Right to Buy)	Options Exercise	$0	-24.6K	-68.75%	$0.00	11.2K	Jan 18, 2022	Common Stock	24.6K	$4.15	Direct	F2
transaction	IKNA	Stock Option (Right to Buy)	Options Exercise	$0	-8.27K	-22.2%	$0.00	29K	Jan 18, 2022	Common Stock	8.27K	$4.51	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option vested and became exercisable on July 16, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2	25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3	25% of this option vested and became exercisable on December 6, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.